MIT’s Langer sells off excipients biotech to break into Biosimilar market
Eagle Pharmaceuticals Inc. has announced its intention to buy Arsia Therapeutics citing its formulation viscosity reduction platform as the driver for the deal.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs